Faron Pharmaceuticals - Innovatiivisia lääketieteen ratkaisuja (Osa 2)

The press release states: “For the first time, data shows 57% of frontline patients who were transfusion-dependent at baseline achieved transfusion independence, confirming restoration of healthy bone marrow function.”

In the ASH poster: “In treatment-naïve HR MDS, 57% of baseline TD patients became TI with BEX+AZA.”

I don’t really understand much of this, but do you really think this is incorrect information? Because I noticed that the poster I linked earlier has been removed from Faron’s website.

1 Like